Advanced Search
Current and Breaking News for Professionals, Consumers and Media



Click here to learn how to advertise on this site and for ad rates.

Patient Issues Author: Staff Editor Last Updated: Nov 29, 2012 - 7:11:02 AM



Cushing's Syndrome Patient Assistance Program

By Staff Editor
Apr 6, 2012 - 3:10:19 PM



Email Newsletter icon, E-mail Newsletter icon, Email List icon, E-mail List icon Sign up for our Ezine
For Email Marketing you can trust


Email this article
 Printer friendly page
(HealthNewsDigest.com) - WASHINGTON, April 6, 2012 -- In partnership with Corcept Therapeutics Inc., the National Organization for Rare Disorders (NORD) has established a Cushing's Syndrome Patient Assistance Program for patients with endogenous Cushing's syndrome who need financial assistance with certain costs related to their medical diagnosis and/or care.

Endogenous Cushing's syndrome is a serious and debilitating rare disorder caused by over-production of cortisol, a steroid hormone that increases blood sugar levels, by the adrenal glands. The syndrome most commonly affects adults between the ages of 25 and 40.

"It is especially appropriate that we are making this announcement just before Cushing's Awareness Day, which will be observed on Sunday," noted NORD President and CEO Peter L. Saltonstall. "The Cushing's Support and Research Foundation (CSRF), a non-profit organization for patients and families affected by Cushing's syndrome, is a member of NORD. We are pleased to join CSRF and the entire Cushing's community in promoting awareness of Cushing's syndrome at this time."

The new program, which launches on April 11, will provide assistance with deductible and/or co-pay expenses to ensure patient access to Korlym(TM), a drug developed by Corcept and approved by the Food and Drug Administration earlier this year.

The program will also provide financial assistance to eligible uninsured and underinsured patients for reasonable expenses required for diagnosis, direct treatment, and care that are not covered by insurance. These would include incidental medical expenses such as lab and diagnostic tests, as well as related expenses such as travel for a medical consultation.

Patients seeking information about the program, or to apply, may contact NORD through a toll free phone number (800 999-6673 Ext. 326) or by email (cushings@rarediseases.org).

Prior to FDA's approval of Korlym(TM) on Feb. 17, 2012, there were no approved medical therapies for the treatment of endogenous Cushing's syndrome. Korlym(TM) is approved for use in patients with endogenous Cushing's syndrome who have type 2 diabetes or glucose intolerance and are not candidates for surgery or have not responded to prior surgery.

NORD is a nonprofit organization, established in 1983, that represents the 30 million Americans with rare diseases. In addition to patient assistance programs, NORD provides programs of advocacy, education, awareness, and research.

Web Site: http://www.rarediseases.org

###

For advertising and promotion on HealthNewsDigest.com please contact Mike McCurdy: tvmike13@HealthNewsDigest.com or 877-634-9180
HealthNewsDigest.com is syndicated worldwide, and our content is free to all media. www.HealthNewsDigest.com

Top of Page

HealthNewsDigest.com

Patient Issues
Latest Headlines


+ 'Doctor Shopping' by Obese Patients Negatively Affects Health
+ How Sunlight May Affect ADHD Patients
+ A 12-Step Program for Knee Replacement
+ Swallowing Disorder - New, Minimally Invasive Procedure Benefits Patients
+ St. Joseph's Children's Hospital Gives Patients a Prom of their Very Own
+ New Antiviral Drugs Clear Hepatitis C in Patients Without Treatment Options
+ Physicians Less Likely to 'Bond' with Overweight Patients
+ AIG Study Shows Hospital C-Suite and Risk Managers Struggle with Maintaining Patient Safety
+ Rice Students Create Way to Keep Cancer Patients Upright for Radiation Treatment
+ Cardiopoietic 'Smart' Stem Cells Show Promise in Heart Failure Patients



Contact Us | Job Listings | Help | Site Map | About Us
Advertising Information | HND Press Release | Submit Information | Disclaimer

Site hosted by Sanchez Productions